The European Guide to Hypertension 2007 is of great importance

this year, the EuropeanSociety for Hypertension (ESH)/EuropeanHeartSociety (ESC) updated the 2007 EuropeanHypertensionGuidelines, which immediately aroused a strong international cardiovascular responseAt the Asia-PacificHigh Blood PressureConference (APCH) held in Beijing recently, experts such as Professor Henry Elliott, a cardiovascular expert from the United Kingdom, Professor Zhang Weizhong and Professor Shi Zhongwei of theof RuijinHospital affiliated with Shanghai Second Medical University, said that the Guide is a good summary of the progress of thebasic, clinical and population research areas ofhypertension in recent years, and has made important updates, and put forward more clinically meaningful and practical diagnosis and treatment recommendationsThe domestic experts at the meeting said that finding a drug treatment program suitable for patients with hypertension in China has always been the goal pursued by the majority of clinicians in China, and the European Hypertension Guide 2007 has important reference significance for the prevention and treatment of hypertension in ChinaThey introduced and discussed the important role of blood pressure thresholds, blood pressure target values and long-acting calcium channel blockers (CCB), and combination drug use in the European Hypertension Guidelines 2007Hypertension treatment focus on standardization and practical
According to experts, the 2007 European Guidelines for Hypertension mainly include: blood pressure threshold, guidelines and practical recommendations of three sub-sections The first section covers the definition and classification of blood pressure thresholds Professor Henry Elliott of the United Kingdom said that according to the European Guidelines for Hypertension 2007, the optimal blood pressure threshold should be less than 120/80 mmHg Normal high blood pressure carries cardiovascular risk as the patient ages, and this risk increases with the increase in blood pressure thresholds In addition, in patients with hypertension with diabetes and chronic kidney disease, the threshold of the initial blood pressure of antihypertensive medication should be lower The second section introduces the requirements for the target value of blood pressure, emphasizing that the reduction of blood pressure will reduce the cardiovascular risk For patients with general hypertension, the target value of blood pressure should be 140/90 mmHg, for patients with simple systolic hypertension, the target value of systolic blood pressure should be 140 mmHg, for patients with diabetes and chronic kidney disease, the target value of blood pressure should be 130/80 mmHg for coronary heart disease, angina Patients, the recommended blood pressure target value should also be 130/80 mm Hg in a large-scale study of long-acting calcium channel blockers - in the ACTION trial, the results of the hypertension subgroup showed that the benefits of nitrobenzene-controlled release tablets compared to comfort significantly reduced cardiovascular events (13%), indicating the significance of the pressure reduction standard to reduce cardiovascular events The third section of the European Hypertension Guide 2007 introduces some practical drug recommendations for the clinical treatment of hypertension, points out that long-acting calcium channel blockers do not have mandatory contraindications, and recommends their use in stroke, simple contraction period hypertension in old age, coronary atherosclerosis hypertension and other treatments The updated British Guidelines for Adult Hypertension, published in 2006 jointly by the British Institute for Clinical Optimization (NICE) and the British Society of Hypertension (BHS), also point out that for patients over 55 years of age, long-acting calcium channel blockers or pyridine diuretics are recommended, and if necessary, the use of angiotensin conversion inhibitors (ACEI), angiotensin receptor antagonists (ARB) The cardiovascular benefits of antihypertensive drugs from combination drugs
the experts highlighted the principle of choice of antihypertensive drugs and the evidence support for the combined use of antihypertensive drugs in large-scale clinical trials According to the Ukadult Hypertension Guidelines, the treatment target for hypertension is 140/90 mmhg or less; it is best to control blood pressure smoothly 24 hours a day, use drugs that are taken with long-acting, once a day; meet the recommended blood pressure target, use a combination of drug therapy strategies; and minimize cardiovascular risk, including treatment sediphin control, lower cholesterol, control blood sugar and anti-blood platelets The FDA's minimum requirement for TP ratios is 50% to 66% Compared with other long-acting calcium channel blockers, the TP ratio of nitrobenzene flat-controlled release tablets is the highest Zanchetti et al have shown that the TP ratio of nitrobenzene flat-controlled release sheets, whether systolic pressure or diastolic pressure, can reach about 100%, with significant advantages The European Guidelines for Hypertension 2007 indicate that the drugs that are most widely combined with other antihypertensive drugs are long-acting calcium channel blockers In the NICE-Combi study, the combined use of low-dose nitrosamines and Kandysatan was more effective in controlling blood pressure and protecting the kidneys in patients with primary hypertension than with the candysatin monodrug In the ADVANCE-Combi study, a combination of nitrosphenyl-controlled release tablets for patients with primary hypertension significantly reduced blood pressure, increased blood pressure compliance, and significantly reduced costs in those with blood pressure In addition, drug co-use can also reduce the of adverse reactions drugs In the ASCOT study, patients treated with long-acting calcium channel blockers and angiotensin conversion enzyme inhibitors (ampicillin/Pepepuri) received significant cardiovascular benefits; (Ma Yanhong)